Frontal EEG predictors of treatment outcome in major depressive disorder

Dan V. Iosifescu, Scott Greenwald, Philip Devlin, David Mischoulon, John W. Denninger, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6% female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9%) responded to treatment (HAM-D-17 reduction ≥ 50%). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21%) in treatment responders than in non-responders (24%). Baseline relative theta power predicted treatment response with 63% accuracy [64% sensitivity, 62% specificity, 66% area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60% accuracy [62% sensitivity, 57% specificity, 61% AUROC (p = 0.089)]. ATR predicted response with 70% accuracy [82% sensitivity, 54% specificity, 72% AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.

Original languageEnglish (US)
Pages (from-to)772-777
Number of pages6
JournalEuropean Neuropsychopharmacology
Volume19
Issue number11
DOIs
StatePublished - Nov 2009
Externally publishedYes

Fingerprint

Major Depressive Disorder
Electroencephalography
Antidepressive Agents
Sensitivity and Specificity
varespladib methyl
Diagnostic and Statistical Manual of Mental Disorders
Power (Psychology)
Venlafaxine Hydrochloride

Keywords

  • Antidepressants
  • Major depressive disorder
  • Quantitative electroencephalography (QEEG)
  • Treatment response

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Biological Psychiatry
  • Pharmacology (medical)

Cite this

Iosifescu, D. V., Greenwald, S., Devlin, P., Mischoulon, D., Denninger, J. W., Alpert, J. E., & Fava, M. (2009). Frontal EEG predictors of treatment outcome in major depressive disorder. European Neuropsychopharmacology, 19(11), 772-777. https://doi.org/10.1016/j.euroneuro.2009.06.001

Frontal EEG predictors of treatment outcome in major depressive disorder. / Iosifescu, Dan V.; Greenwald, Scott; Devlin, Philip; Mischoulon, David; Denninger, John W.; Alpert, Jonathan E.; Fava, Maurizio.

In: European Neuropsychopharmacology, Vol. 19, No. 11, 11.2009, p. 772-777.

Research output: Contribution to journalArticle

Iosifescu, DV, Greenwald, S, Devlin, P, Mischoulon, D, Denninger, JW, Alpert, JE & Fava, M 2009, 'Frontal EEG predictors of treatment outcome in major depressive disorder', European Neuropsychopharmacology, vol. 19, no. 11, pp. 772-777. https://doi.org/10.1016/j.euroneuro.2009.06.001
Iosifescu, Dan V. ; Greenwald, Scott ; Devlin, Philip ; Mischoulon, David ; Denninger, John W. ; Alpert, Jonathan E. ; Fava, Maurizio. / Frontal EEG predictors of treatment outcome in major depressive disorder. In: European Neuropsychopharmacology. 2009 ; Vol. 19, No. 11. pp. 772-777.
@article{1ec4b0610c3848628a31ca37d9af1182,
title = "Frontal EEG predictors of treatment outcome in major depressive disorder",
abstract = "Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6{\%} female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9{\%}) responded to treatment (HAM-D-17 reduction ≥ 50{\%}). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21{\%}) in treatment responders than in non-responders (24{\%}). Baseline relative theta power predicted treatment response with 63{\%} accuracy [64{\%} sensitivity, 62{\%} specificity, 66{\%} area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60{\%} accuracy [62{\%} sensitivity, 57{\%} specificity, 61{\%} AUROC (p = 0.089)]. ATR predicted response with 70{\%} accuracy [82{\%} sensitivity, 54{\%} specificity, 72{\%} AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.",
keywords = "Antidepressants, Major depressive disorder, Quantitative electroencephalography (QEEG), Treatment response",
author = "Iosifescu, {Dan V.} and Scott Greenwald and Philip Devlin and David Mischoulon and Denninger, {John W.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2009",
month = "11",
doi = "10.1016/j.euroneuro.2009.06.001",
language = "English (US)",
volume = "19",
pages = "772--777",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Elsevier",
number = "11",

}

TY - JOUR

T1 - Frontal EEG predictors of treatment outcome in major depressive disorder

AU - Iosifescu, Dan V.

AU - Greenwald, Scott

AU - Devlin, Philip

AU - Mischoulon, David

AU - Denninger, John W.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2009/11

Y1 - 2009/11

N2 - Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6% female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9%) responded to treatment (HAM-D-17 reduction ≥ 50%). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21%) in treatment responders than in non-responders (24%). Baseline relative theta power predicted treatment response with 63% accuracy [64% sensitivity, 62% specificity, 66% area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60% accuracy [62% sensitivity, 57% specificity, 61% AUROC (p = 0.089)]. ATR predicted response with 70% accuracy [82% sensitivity, 54% specificity, 72% AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.

AB - Objective: To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD). Method: 82 subjects (age 35.9 ± 13.0; 47.6% female) meeting DSM-IV criteria for MDD entered an 8-week prospective treatment with SSRIs or venlafaxine. At baseline and week 1 we recorded serial, 4-channel EEGs (F7-Fpz, F8-Fpz, A1-Fpz, A2-Fpz). We evaluated prospectively the relative theta power as predictor of treatment outcome. We also developed an Antidepressant Treatment Response (ATR) index using EEG parameters assessed at baseline and week 1. Results: 45 subjects (54.9%) responded to treatment (HAM-D-17 reduction ≥ 50%). At baseline, frontal relative theta power (i.e., 4-8 Hz power/2-20 Hz power) was significantly (p = 0.017) lower (21%) in treatment responders than in non-responders (24%). Baseline relative theta power predicted treatment response with 63% accuracy [64% sensitivity, 62% specificity, 66% area under the receiver operator curve (AUROC) (p = 0.014)]. Relative theta power at week 1 predicted treatment response with 60% accuracy [62% sensitivity, 57% specificity, 61% AUROC (p = 0.089)]. ATR predicted response with 70% accuracy [82% sensitivity, 54% specificity, 72% AUROC (p = 0.001)]. Conclusion: Using automated analysis of frontal EEG collected during the first week of antidepressant treatment it may be possible to facilitate prediction of SSRI or venlafaxine efficacy in MDD.

KW - Antidepressants

KW - Major depressive disorder

KW - Quantitative electroencephalography (QEEG)

KW - Treatment response

UR - http://www.scopus.com/inward/record.url?scp=70349487527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349487527&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2009.06.001

DO - 10.1016/j.euroneuro.2009.06.001

M3 - Article

VL - 19

SP - 772

EP - 777

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 11

ER -